title: [Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis].
abstract: OBJECTIVE
  To observe the therapeutic effect of tiotropium bromide powder inhalation on stable bronchiectasis.
  
  
  METHODS
  Twenty-two patients with stable bronchiectasis received inhalation of totropium bromide powder at the daily dose of 18 microg, and on days 1 and 28, the patients were examined for forced expiratory volume in one second (FEVl), predicted value [FEVl(%)], forced expiratory volume (FEV), and FEVl/FVC. The symptom score and BODE index were also recorded.
  
  
  RESULTS
  After 1 month of inhalation therapy, the FEV1% of the patients showed a moderate increase but the increment was not statistically significant (t=-1.875, P>0.05); the symptom score and BODE index decreased significantly after the therapy (t=7.091, P<0.001; t=2.982, P<0.05).
  
  
  CONCLUSIONS
  Long-term inhalation of tiotropium bromide powder can improve the clinical symptoms and BODE index and enhance the exercise tolerance and quality of life of the patients with bronchiectasis.
authors.affiliation: Department of Respiratory Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. myxiao2000@126.com
authors.forename: Xiao-ling
authors.initials: XL
authors.lastname: Li
authors.forename: Shao-xi
authors.initials: SX
authors.lastname: Cai
authors.forename: Hai-jin
authors.initials: HJ
authors.lastname: Zhao
authors.forename: Li-min
authors.initials: LM
authors.lastname: Dong
authors.forename: Xiang-bo
authors.initials: XB
authors.lastname: Shen
authors.forename: Lai-yu
authors.initials: LY
authors.lastname: Liu
authors.forename: Guo-dong
authors.initials: GD
authors.lastname: Hu
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D001987:Bronchiectasis / Q000188:drug therapy*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D011208:Powders; D043587:Receptor, Muscarinic M3 / Q000037:antagonists & inhibitors*; D012602:Scopolamine Derivatives / Q000008:administration & dosage*; D000069447:Tiotropium Bromide
chemical_list: D011208:Powders; D043587:Receptor, Muscarinic M3; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide